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The H5N1-clade 1 influenza vaccine strain NIBRG-14 produces exceptionally low amounts of antigen, 
a problem recently encountered also for initial pandemic H1N1-2009 vaccine seeds. Here, we report 
on a strategy that may contribute to overcome this obstacle. Influenza vaccine viruses usually consist 
of two segments coding for the antigenic HA and NA proteins of a wild-type strain and the six residual 
internal gene segments of the vaccine donor strain A/PR/8/34 (PR8). To enhance the antigen yield 
from H5N1 vaccine virus we generated by reverse genetics a set of PR8-based reassortant viruses 
expressing the HA and NA segments of the prototypic strain A/Vietnam/1203/2004 and additional 
replacements of the internal M or PB1 genes of PR8. The reassortants were compared to the parental 
PR8 and H5N1 viruses in terms of growth in embryonated chicken eggs and the amount of 
incorporated antigenic HA protein. Compared to NIBRG-14, three out of six viruses displayed an 
increased replication in embryonated chicken eggs and higher HA content that was also maintained 
after ether/detergent extraction of virions. Electron microscopic analysis showed that the reassortment 
hardly affected particle shape and size. Two selected H5N1 reassortant viruses were investigated 
concerning their pathogenicity in ferrets and found to behave as low pathogenic as the PR8 donor 
strain. In conclusion, this study shows that replication and antigen content of PR8-derived H5N1 
influenza vaccine viruses can be improved by incorporation of heterologous internal gene segments 
without compromising their attenuated character. 
 
1. Introduction 
After the first infections of humans by influenza A viruses of the H5N1 subtype in Hong Kong in 1997 
considerable efforts have been made to develop an effective vaccine against H5N1 influenza in 
humans. As of August 2010, a total of 504 human H5N1 cases have been registered by WHO with a 
stunning case fatality rate of about 60% 
(http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_08_12/en/index.html). So 
far, the low transmissibility among humans prevented epidemic or pandemic spread of H5N1 viruses 
[1] and [2]. However, a novel swine-origin H1N1 influenza virus (S-OIV, here referred to as H1N1-
2009) appeared in North America in early 2009 and caused infections on a global scale within a few 
months triggering hasty developments of corresponding pandemic vaccines [3] and [4]. In June 2009 
the WHO raised the pandemic alert to phase 6. Infections by the H1N1-2009 virus had been detected 
in at least 214 countries and territories (http://www.who.int/csr/don/2010_08_06/en/index.html) before 
the post-pandemic status was declared on August 10th 2010. 
Inactivated influenza A vaccines are usually generated with the apathogenic PR8 strain, known to 
grow to high titres in embryonated chicken eggs, by using either classical reassortment or reverse 
genetic methods [5], [6] and [7]. For classical reassortment, embryonated chicken eggs are co-infected 
with a circulating wild-type (WT) virus and the PR8 vaccine donor strain. Progeny viruses are 
screened for 6 + 2 reassortants containing the six internal gene segments of PR8 and the antigenic 
  
HA and NA genes coding for the surface glycoproteins of the WT strain [8]. The use of reverse 
genetics has the advantage that reassortant viruses with the desired gene constellation can be 
rescued directly from tissue culture cells transfected with cloned viral cDNAs [9], [10] and [11]. In 
addition, this procedure allows the removal of virulence determinants from viral proteins such as an 
oligobasic cleavage site within the HA protein. Many commercial manufacturers produce well tolerated 
seasonal “split vaccines” in which the bulk of vaccine virus is chemically inactivated and extracted with 
detergents and organic solvent to separate the immunogenic surface glycoproteins from reactogenic 
compounds [12] and [13]. The currently available H5N1 vaccines were shown to be safe and 
immunogenic when formulated as split-, adjuvanted whole virion- or subvirion vaccine [14], 
[15] and [16]. 
The influenza A/Vietnam/1203/2004 (VN1203) and A/Vietnam/1194/2004 (VN1194) viruses were 
recommended by WHO as prototypic clade 1 H5N1 strains for the generation of pre-pandemic 
vaccines in the year 2005. One of the first prototypic H5 vaccine strains termed NIBRG-14 was based 
on the PR8 backbone and carried the two gene segments encoding for HA and NA of VN1194, in 
which the HA gene had been modified to encode a monobasic cleavage site [17]. However, when 
NIBRG-14 was used for vaccine preparations in embryonated chicken eggs antigen yields were 
reported to be drastically lower compared to yields achieved with seasonal vaccine strains [18]. This 
was possibly caused by suboptimal interaction(s) between internal PR8 gene products and the 
heterologous H5N1 surface glycoproteins. A subsequent study confirmed the low HA content of 
NIBRG-14 compared to two other H5 vaccine and wild type viruses [19]. A similar problem was 
recently also encountered for reassortant vaccine seeds targeting the pandemic H1N1-2009 virus [20]. 
The poor growth of the initial pandemic H1N1-2009 vaccine viruses resulted in a considerable 
shortage and delay in the distribution of H1N1 vaccine extending the period of time during which risk 
groups could not be protected by immunoprophylaxis. For an optimal control of pandemic and 
seasonal influenza it is therefore needed to explore strategies to overcome such a potential shortage 
in vaccine production. 
One possibility to enhance the antigen yield of influenza vaccine strains could be the substitution of 
internal genes of the PR8 donor such as the polymerase complex or M segments. The M1 protein is 
located underneath the particle membrane [21] and is described to interact with the virus surface 
glycoproteins as well as with the vRNPs in the virus particle [22] and [23]. This interaction is thought to 
be essential for assembly and budding of virus particles [22]. Moreover, the cytoplasmic tail of the M2 
protein was found to be involved in the production of new virus particles and the efficient packaging of 
virus genomes [24] and [25]. As the PR8-M proteins may not interact optimally with the HA and NA 
proteins of H5N1 strains we hypothesized that M segments from other strains could influence the 
growth and possibly antigen yield of H5N1 influenza vaccine viruses. Moreover, several high-yielding 
H3N2 vaccine viruses generated by classical reassortment had retained the PB1 segment of the 
seasonal virus indicating this incorporation to be beneficial for virus production [26]. Also, the H1N1-
2009 seed strain A/reassortant/NYMC X-179A harboured the PB1 gene segment and the surface 
glycoprotein genes of the prototypic A/California/07/2009 strain (Genbank accession GQ214335). 
With those findings in mind we generated by reverse genetics a set of PR8-based reassortant viruses 
carrying the HA and NA gene segments of VN1203, in which also the internal M or PB1 segments 
were replaced (5 + 2 + 1 reassortants). This set of viruses was compared to the NIBRG-14 vaccine 
strain in terms of replication in embryonated chicken eggs and HA content. Overall, we identified two 
H5N1 candidate vaccine viruses with enhanced growth and incorporated HA protein, which was also 
maintained under conditions of split vaccine preparation. Infections of ferrets with these two selected 
viruses demonstrated that they behaved as benign as the parental A/PR/8/34 virus confirming their 
suitability for vaccine production under normal biosafety level. Hence, this study shows that 
modifications of the PR8 background can optimize influenza vaccine seed viruses. 
  
2. Materials and methods 
 
2.1. Cells and viruses 
293T cells were grown in Dulbecco's modified eagle medium (D-MEM) supplemented with 10% fetal 
calf serum, l-glutamine (2 mM) and penicillin/streptomycin (100 μg/ml). Madin Darby canine kidney 
cells (MDCK II) were grown in minimum essential medium (MEM) supplemented as described above. 
All the cells were maintained at 37 °C and 5% CO2. The H5N1-clade 1 vaccine strain NIBRG-14 and 
the A/Vietnam/1203/2004 WT virus were obtained from the National Institute for Biological Standards 
and Control (NIBSC, Hertfordshire, UK). Recombinant A/Vietnam/1203/04 wild type viruses with multi- 
(VN1203-hp) or monobasic (VN1203-lp) cleavage site were generated by reverse genetic methods in 
our laboratory [27]. Site-directed mutagenesis was used to replace the multibasic cleavage within in 
the corresponding HA plasmid from “RERRRKKRG” to the monobasic sequence “RETRG”. 
 
2.2. Plasmids 
RNA polymerase I (pol I)-driven expression plasmids for the eight gene segments of influenza 
A/PR/8/34 virus, pPol I plasmids encoding the vRNAs of the VN/1203 NA and HA with a monobasic 
cleavage site (HA-VN1203-lp) and pCAGGS plasmids expressing the A/PR/8/34 viral proteins PB2, 
PB1, PA and NP proteins were kindly provided by Peter Palese (Mt. Sinai School of Medicine, New 
York) [11]. The vector containing the M gene of A/chicken/R28/Germany/2003 (H7N7) was obtained 
from the Institute of Virology, University of Marburg, Germany. The cDNA of the A/Panama/2007/99M 
gene (Genbank accession DQ487338) was cloned into the pHW2000 expression vector [9] by 
standard methods. 
 
2.3. Production of recombinant viruses 
Reassortant and recombinant viruses were generated by the 12-plasmid reverse genetic system as 
described by Fodor et al. [11]. Briefly, plasmids were transfected into 293T cells with Lipofectamin 
2000 (Invitrogen) according to manufacturer's instructions and cells were incubated for two days at 
37 °C. Subsequently, supernatants of transfected 293T cells were harvested and inoculated in 10-day-
old embryonated chicken eggs. Eggs were incubated for 48 h at 37 °C and the allantoic fluid was 
harvested, clarified and tested for hemagglutination and plaque assays. 
 
2.4. Quantification of virus titres 
To determine the growth capability of a given virus five specific pathogen-free 11-day-old embryonated 
chicken eggs (Lohmann Tierzucht, Cuxhaven, Germany) were inoculated with 10e3 PFU from the 
corresponding second passage after virus rescue. Eggs were incubated for 48 h at 37 °C. For the high 
and low pathogenic versions of the VN1203 virus incubation time was decreased to 41 h to avoid 
excessive cytopathic effects. The allantoic fluids of the five inoculated eggs were harvested and 
clarified by centrifugation (3000 rpm, 10 min, 4 °C) and serial dilutions of each virus stock were 
inoculated into 11-day-old embryonated chicken eggs to determine the minimal egg infectious dose 
(EID50/ml). After a 48 h incubation period (41 h for recombinant VN1203 viruses), the allantoic fluids 
were collected and assayed for the presence of virus by hemagglutination. The EID50/ml was 
determined by the formula of Reed and Muench [28]. To determine virus titres in organ homogenates, 
MDCK II cells were seeded in 96-well plates (flat bottom) one day prior to infection. A series of log 
step dilutions of homogenized organ samples or swabs were made in infection medium (MEM, 0.2% 
bovine albumin, 20 mM glutamine, 1 μg/ml TPCK-treated trypsin plus antibiotics). Cells were washed 
twice and infected with the homogenates using a total of 5 replicates per dilution. Tissue cultures were 
incubated at 37 °C for 72 h, fixed with paraformaldehyde and stained with crystal violet. The tissue 




2.5. Deglycosylation and analysis of virion proteins 
Viruses were purified from the allantoic fluids of 11-day-old embryonated chicken eggs by low-speed 
clarification (3000 rpm, 10 min, 4 °C) followed by centrifugation through a 25% sucrose cushion in a 
SW28 rotor (24,000 rpm, 90 min, 4 °C). The virus pellet was resuspended in PBS and the total amount 
of purified virion proteins was determined by standard BCA protein assay (Thermo Scientific). 20 μg of 
total protein was denatured according to the manufacturer's instructions and subsequently digested 
with 10 U PNGase F (New England Biolabs) for 16 h at 37 °C as described [19]. Samples were mixed 
after overnight digestion with loading dye and heated to 95 °C for 5 min prior to separation by SDS gel 
electrophoresis and visualization by Coomassie staining was done by using The Li-Cor Odyssey 
imaging system and the application software version 2.1 (Li-Core Biosciences) were used for 
quantification of single protein bands. Protein amounts were adjusted to equal amounts of NP protein 
and HA/NP ratios were calculated. 
 
2.6. Ether/detergent extraction of viral glycoproteins 
Virions were purified from allantoic fluid as described above and resuspended in PBS followed by 
addition of an equal volume of an ether/Tween-80 (0.01%) mixture [29]. The samples were stirred for 
30 min at room temperature and were subsequently centrifuged for 2 min at 12,000 rpm. The aqueous 
phase was collected, treated with PNGase F as described above and the viral proteins were separated 
and visualized by SDS-PAGE and Coomassie staining. 
 
2.7. Analysis of virion particles by immunogold electron microscopy 
Virus particles were concentrated by ultracentrifugation as described above and fixed with a final 
concentration of 2% paraformaldehyde in 0.05 M HEPES buffer. Virus particles were adsorbed onto a 
carbon reinforced plastic film that was supported by a copper grid, by putting the grid on a drop of the 
virus suspension for 10 min. After adsorption of virus particles, grids were transferred over a sequence 
of droplets (30 μl) of the following solutions for immuno-negative staining: 50 mM glycine (in PBS), 
0.1% bovine serum albumin (BSA) diluted in PBS, primary antibody (diluted in 0.1% BSA), 0.1% BSA 
(3 times), secondary antibody (coupled to 5 nm of gold and diluted with 0.1% BSA), PBS (3 times), 
double distilled water (5 times), and uranyl acetate (1% in water). Incubation time at room temperature 
was 10 min for glycine, BSA and secondary antibody and 15 min for the primary antibody. All washing 
steps were performed for 1 min. The primary antibody was a purified monoclonal mouse antibody 
raised against H5-HA (anti-H5HA-22/03/D9-3/D10) that was kindly provided by the National Reference 
Centre for Influenza at the Robert Koch-Institute. Grids were inspected with a transmission electron 
microscope (Tecnai12 BioTwin; FEI) and images of virus particles were recorded with a 1k 
(MegaviewIII; OSIS) or a 2k CCD-camera (TVIPS F214; Tietz). Area and circumference of randomly 
selected virus particles were measured as projected by the microscope using the iTEM-software 
(OSIS, Germany) and manual segmentation of virus particles. 
 
2.8. Infection of ferrets 
Female outbred ferrets were obtained from Schimmel (the Netherlands). The ferret safety testing was 
conducted according to WHO guidelines [30] and was approved by a local committee and done in 
accordance with national guidelines for the care and use of laboratory animals. All ferrets were kept in 
quarantine 14 days prior to infection and were screened for Aleutian Disease and previous influenza 
virus infections. For the study 4 groups of 6 ferrets between 16 and 32 weeks of age were intranasally 
infected under anaesthesia with 0.5 ml containing 10
7
 TCID50 of either the high pathogenic 
A/Vietnam/1203/2004 H5N1 WT strain, the reassortant PR8-HA VN1203 (R#2), the reassortant PR8-
HA/NA VN1203-M Pan99 (R#4) or the A/PR/8/34 vaccine donor strain. Each group was divided into 
two subgroups (A and B) and nasal swabs were obtained from all animals prior to infection and from 
day one until day 3 post infection (p.i.) for virological analysis. Animals of subgroup A were sacrificed 
at day 3 p.i. and samples were taken from the lungs, brain, spleen and nasal turbinates for storage at 
−70 °C and subsequent virological analysis. Animals of subgroup B were followed for disease 
  
development for two weeks. To this end, animals were weighed and clinical signs (respiratory disease, 
activity and neurological symptoms) were recorded daily from day −2 until day 3 p.i., thereafter every 
second day. Body temperature was monitored every 30 min by a transplanted temperature logger 
(DST micro-T, StarOddi). For virus titration, frozen samples (day 3 p.i.) were thawed, weighed and 
transferred to lysing D matrix tubes (MP Biomedical) containing 1.4 mm ceramic spheres (lung, brain, 
spleen) or lysing A matrix tubes containing garnet shards and a 1/4″ ceramic sphere (trachea, nasal 
turbinate). 0.2 ml PBS/0.1 g tissue was added to the tubes and organs were homogenized in a 
FastPrep24 homogenizer (MP Biomedical). Thereafter, tubes were centrifuged twice and clarified 




3.1. Generation of recombinant influenza A viruses 
Using plasmid-based reverse genetics [11] we generated a panel of PR8-based reassortant viruses 
with glycoprotein genes of the prototypic H5N1 strain VN1203 and additional replacement by the M or 
PB1 segments derived from human or avian strains (Fig. 1). This set included a recombinant PR8 WT 
virus (PR8; #1), the reassortant #2 encoding the HA protein of VN1203 with an engineered monobasic 
cleavage site and seven segments of PR8 (PR8-HA VN1203), and the reassortant #3 consisting of six 
internal PR8 segments and both viral surface glycoproteins of VN1203 (PR8-HA/NA VN1203). The 
reassortants #4–#6 carry replacements of the M segment derived from human or avian strains, 
respectively, in addition to the VN1203 surface glycoproteins genes: Reassortant #4 contains the M 
segment of the seasonal A/Panama/2007/99 (Pan99) virus (PR8-HA/NA VN1203-M Pan99), 
reassortant #5 carries the M segment of A/chicken/Germany/R28/2003 (H7N7) (PR8-HA/NA VN1203-
M R28), whereas reassortant #6 expresses the M segment of VN1203 (PR8-HA/NA/M VN1203). 
Reassortant #7 comprises the PB1, HA and NA gene segments of VN1203 (PR8-HA/NA/PB1 
VN1203). The prototypic NIBRG-14 H5N1 vaccine virus encoding the glycoprotein genes of VN1194 
was obtained from NIBSC and was included in our analysis as reassortant #8. Reassortant #9 
includes the H3N2 glycoprotein genes of the seasonal Pan99 strain in the PR8 background (PR8-
HA/NA Pan99) and served as a control. Furthermore, two recombinant H5N1 viruses with all eight 
segments of the VN1203 virus were generated, which differed only in the monobasic (VN1203-lp; #10) 
or multibasic cleavage site in the HA (VN1203-hp; #11). All viruses were passaged twice in 
embryonated chicken eggs before their growth behaviour and protein content were examined. 
 
3.2. Identification of H5N1 reassortant viruses with enhanced growth in embryonated chicken 
eggs compared to NIBRG-14 
High titre growth in embryonated chicken eggs is a prerequisite to achieve high antigen yields from 
influenza vaccine viruses. The growth capabilities of the generated recombinant/reassortant viruses in 
chicken eggs were compared with the parental recombinant PR8, the NIBRG-14 vaccine strain and 
the high- and low-pathogenic VN1203 viruses. Fig. 2 shows the mean viral titres for each virus 
determined in five independent experiments. The six reassortant viruses PR8-HA VN1203 [#2] 
(2.8 × 10
9
 EID50/ml), PR8-HA/NA VN1203 [#3] (3.1 × 10
9
 EID50/ml), PR8-HA/NA VN1203-M Pan [#4] 
(2.7 × 10
9
 EID50/ml), PR8-HA/NA/M VN1203 [#6] (1.4 × 10
9
 EID50/ml) as well as the recombinant PR8 
[#1] (3.6 × 10
9
 EID50/ml) and A/Vietnam/1203/2004-lp viruses [#10] (2.1 × 10
9
 EID50/ml) replicated to 
higher mean titres than NIBRG-14 [#8] (1.2 × 10
9
 EID50/ml). In contrast, the reassortant viruses with 
the M segment of A/chicken/Germany/R28/2003 [#5], the PB1 gene of VN1203 [#7], or the 
glycoprotein genes of A/Panama/2007/1999 [#9] replicated to lower mean titres (#5: 
7.3 × 10
8
 EID50/ml; #7: 4.2 × 10
8
; #9: 6.6 × 10
8
 EID50/ml). The recombinant A/Vietnam/1203/2004-hp 
[#11] showed the lowest growth among all tested viruses (2.5 × 10
8
 EID50/ml). These results suggest 
that the growth of PR8 derived 6 + 2 reassortant viruses can be modulated by replacement of an 




3.3. Comparison of surface glycoprotein incorporation in reassortant virions 
For high vaccine yield it is required that the corresponding virus incorporates a high amount of 
immunogenic HA and NA surface glycoproteins, in addition to efficient viral growth. We therefore 
evaluated whether the exchange of internal gene segments would influence this property. To compare 
the levels of virion proteins within the set of recombinants we purified viruses from egg allantoic fluid 
by centrifugation through a sucrose cushion followed by SDS gel analysis. Fig. 3A shows that HA and 
NA proteins are highly glycosylated and therefore not easily distinguishable by SDS-gel analysis 
without modification. Hence, the oligosaccharide side chains were removed from HA and NA in the 
purified virions by deglycosylation with PNGaseF prior to analysis by gel electrophoresis and total 
protein staining. The amounts of the virion preparations were adjusted to equal NP protein signals 
before they were separated by standard gel electrophoresis (Fig. 3B). This allowed the quantification 
of single viral protein bands by densitometric analysis and enabled the calculation of HA1/NP ratios 
that was arbitrarily set to 1 for NIBRG-14. Subsequently, the x-fold differences between NIBRG-14 and 
other investigated viruses were determined. 
Here it was found that the two reassortants #4 (PR8-HA/NA VN1203-M Pan99) and #5 (PR8-HA/NA 
VN1203-M R28), containing a replacement of the M segment exhibited 3.2- and 3.7-fold increases in 
the HA1/NP ratio compared to NIBRG-14, which were statistically significant (Fig. 3C). Slightly lower 
enhancements in the HA1/NP ratio were found for reassortants #6 (PR8-HA/NA/M VN1203), #7 (PR8-
HA/NA/PB1 VN1203), #2 (PR8-HA VN1203) and the parental PR8 virus (2.3-, 1.9-, 1.7-, and 1.8-fold, 
respectively). Additionally, we included the recombinant VN1203-lp virus in our experiments to 
investigate the HA1/NP ratio in a mere H5N1 virus in comparison to the reassortant viruses. We found 
that the recombinant wild type virus differed only slightly in its HA1/NP ratio (1.7-fold) from NIBRG-14. 
Together these data clearly indicate that the amount of virion-incorporated H5-HA protein is influenced 
by the replacements of the M and PB1 segments with homologs of other strains. 
 
3.4. Effect of ether/detergent extraction on HA content of reassortant viruses 
Many influenza vaccine preparations involve an extraction step with ether/detergent solution in which 
reactogenic compounds are removed from the antigenic glycoproteins. However, this procedure might 
also influence the relative amount of HA in the soluble fraction. We therefore addressed the question 
whether the enhanced HA/NP ratio observed for some of the reassortant viruses was retained in the 
soluble antigen preparation after such a treatment. Purified virus suspensions of the selected viruses 
#1, #2, #4, #8 and #10 were extracted with an ether/Tween-80 (0.01%) solution and oligosaccharide 
chains were removed from the HA and NA proteins in the soluble phase by PNGase digestion. The 
SDS gel analysis of the samples showed that the favourable HA/NP ratio particularly of reassortant #4 
was maintained during the extraction procedure (Fig. 3D). 
 
3.5. Replacements of M segments do not influence particle shape of H5N1 reassortant 
influenza viruses 
It has been described that the viral morphogenic M1 and M2 proteins influence the structure of 
influenza A virus particles by specifying a spherical or rather filamentous virion shape [31], 
[32] and [33]. We therefore assessed by immuno-negative staining electron microscopic analyses 
whether alterations in the HA content of the generated reassortant viruses were associated with 
changes in the principle particle morphology or size (area and circumference). This analysis was 
conducted with purified virions from NIBRG-14, the reassortants #2 (PR8-HA VN1203), #4 (PR8-
HA/NA VN1203-M Pan99) and #5 (PR8-HA/NA VN1203-M R28), as well as from the parental PR8 
(#1) and VN1203-lp viruses (#10). Immunolabelling of virus particles with primary anti-H5-HA antibody 
and a secondary immunogold labelled antibody was done to visualize the presence of HA at the virus 
surface. Fig. 4 shows representative micrographs for the recombinant PR8 (#1), the VN1203-lp (#10), 
NIBRG-14 (#8) and the PR8-HA/NA VN1203-M Pan (#4) viruses. As expected, the H5-HA antibody 
stained all H5 subtype viruses with the exception of PR8 that belongs to the H1 subtype. In general, 
there were no major differences in the spherical shapes of the viruses. Analysis of one hundred 
particles for each virus showed that the H5N1 reassortants #2, #4 and #5 exhibited a slightly higher 
mean virion area (8124–8774 nm
2
) compared to PR8 (7244 nm
2
) and NIBRG-14 (7809 nm
2
) with little 
  
differences in the mean circumferences (Table 1). Virions of the VN1203-lp virus (#10) displayed the 
highest mean area value (8979 nm
2
). Overall, these experiments showed that the reassorted gene 
segments did not cause major differences in virion shape or size. 
 
3.6. Integrative assessment of H5N1 reassortant viruses 
The set of reassortants contained representatives with both higher and lower EID50/ml titres and 
HA/NP ratios, respectively, than NIBRG-14. These two parameters were arbitrarily set to 1 for NIBRG-
14. To identify the most promising candidates for high yielding strains we first calculated the relative 
EID50/ml value and the relative HA1/NP ratio of each virus in comparison to NIBRG-14. Subsequently, 
these two parameters were multiplied to obtain a total relative score for each virus. These estimates 
are depicted in Table 2 showing that the replacement of the PR8-M segment with the M segment of 
Pan99 in reassortant #4, which resulted in an increased HA1/NP ratio and decent viral growth, 
achieved the highest score of 7.4. The two other viruses with heterologous M segments, reassortants 
#5 (PR8-HA/NA VN1203-M R28) and #6 (PR8-HA/NA/M VN1203), respectively, also showed 
increased HA1/NP ratios. The high HA content was, however, accompanied by less pronounced mean 
EID50/ml values that still resulted in improvement factors of 2.2-fold and 2.8-fold towards NIBRG-14. 
The 7 + 1 reassortant containing the HA segment of VN1203 in the PR8 background (#2) replicated to 
similar high titres, but displayed a slightly lower HA1/NP ratio leading to an improvement score of 4.1. 
Overall, this analysis identified the reassortants #2 and #4 as the most promising candidates with 
enhanced growth and HA content for further development. 
 
3.7. Selected H5N1 reassortant viruses are strongly attenuated in ferrets 
PR8-based reassortant viruses to be used for the regular production of inactivated vaccine towards 
high pathogenic H5N1 strains need to be shown to behave non pathogenic [30]. The reduced 
pathogenicity of the reassortants #2 and #4 was first indicated by their inability to form plaques in 
tissue culture in the absence of trypsin (data not shown). To assess the virulence potential of the two 
candidate viruses #2 and #4 in vivo we compared their pathogenicity in ferrets to the highly pathogenic 
H5N1 wild-type strain VN1203 and the parental PR8. Four groups of 6 ferrets were infected 
intranasally with 0.5 ml containing 10
7
 TCID50 of either A/Vietnam/1203/2004 (positive control), 
A/PR/8/34 (negative control), the 7 + 1 reassortant (PR8-HA VN1203, #2) or the 5 + 2 + 1 reassortant 
(PR8-HA/NA VN1203-M Pan, #4). Virus titres in nasal swabs were determined from day 1 to 3. Each 
group was subdivided into subgroups A and B, in which animals from subgroup A were sacrificed on 
day 3 to determine viral loads in organ samples, whereas ferrets in subgroup B were followed for 
clinical disease for 14 days. In all analysed nasal swabs taken during the first three days, both parental 
viruses and the two reassortants were detected (Fig. 5). Intranasal virus titres in animals infected with 
the two reassortants or PR8 peaked on day 2 but were strongly reduced on day 3 p.i. In contrast, 
intranasal VN1203 titres remained at high level throughout day 3. As expected, the VN1203 WT virus 
was re-isolated from the brains of three animals (Fig. 6A) and the lungs of two ferrets (Fig. 6B) 
reflecting the pathogenic phenotype. Contrary, neither the parental PR8 vaccine donor nor the two 
reassortant viruses PR8-HA/NA VN1203-M Pan (R#4) and PR8-HA VN1203 (R#2) were detected in 
the lungs or brains. Also in the spleen, the highest virus titres were measured for the wild type VN1203 
strain, whereas very low titres were found for PR8 in two animals and in only one ferret for reassortant 
#2 (Fig. 6C). In nasal turbinates, the VN1203 virus replicated up to titres in the range of 10
7
 TCID50/ml 
(Fig. 6D). Reassortant #4 replicated in the nasal turbinates, but to a low extent, whereas PR8 or R#2 
was not detected at all in such specimen (Fig. 6D). 
None of the subgroup B animals that were infected with the reassortant strains or the parental PR8 
died or had to be terminated during the two week observation period. In contrast, one of the three 
ferrets infected with the VN1203 virus died at day 2 and another animal was sacrificed at day 6 
because it had reached the clinical end point of severe neurological disease. In addition, clinical signs 
of respiratory disease, decrease in activity and neurological symptoms were recorded for the H5N1 
wild-type infected animals (data not shown). The two reassortant strains induced less fever than the 
PR8 donor strain, which in turn induced less fever than the H5N1 virus. Finally, the ferrets infected 
with the reassortant and PR8 donor strains clearly lost less weight than the H5N1 WT-infected animals 
(data not shown). Taken together, these results demonstrate a strong attenuation of the two generated 
H5N1 reassortant viruses in ferrets, as they were not detected in the lung and brain similarly as was 
shown in parallel for the low pathogenic donor strain PR8. Moreover, the degree of disease induced 
  
by the reassortant strains was comparable to the low pathogenic PR8 strain and clearly attenuated 
compared to the severe infections caused by the highly pathogenic H5N1 WT virus. 
 
4. Discussion 
The rapid generation and large scale production of a matched vaccine virus is a major challenge for 
global health during a pandemic influenza outbreak to protect individuals against infection with a novel 
virus strain [20] and [34]. In such a situation it is required to have immediate access to a well growing 
vaccine virus that incorporates a high amount of the major protective viral antigen HA into its surface 
membrane. However, experiences in recent years showed that the strategy to produce 6 + 2 
reassortants of the PR8 strain may deliver vaccine viruses such as NIBRG-14 with less than average 
growth and/or antigen yield [18] and [19]. Here, we explored the concept that reverse genetics could 
be used to generate influenza vaccine seed viruses with improved growth characteristics through 
modification of the PR8 backbone. To this purpose a set of H5N1-PR8 reassortant influenza viruses 
with M or PB1 segments derived from avian or human strains were generated and investigated 
regarding replication in embryonated chicken eggs and HA content. We chose this strategy as the viral 
M1 protein interacts with surface glycoproteins and contributes to virus assembly [22], whereas the 
cytoplasmic tail of the M2 protein is required for efficient genome packaging [24] and also contributes 
to virus assembly [35]. The PB1 gene was included as it was inherited in some circumstances from a 
seasonal WT isolate or the pandemic H1N1-2009 virus to the corresponding vaccine strains during 
classical reassortment. Possibly, this was due to an increase in viral polymerase activity [36]. 
Interestingly, three reassortant viruses in which the M segment of PR8 had been replaced showed an 
increased HA content compared to NIBRG-14. The M gene of the human Pan99 strain in addition also 
increased viral growth by more than 2-fold. Importantly, the enrichment in the HA level was maintained 
after ether/detergent extraction of virions, a common procedure used during split vaccine preparation. 
The encoded gene products of the Pan99-, R28- and VN1203-M segments are identical to their PR8 
homologues in the range of 92.9–95.7% for the M1 protein and 80.6–88.8% for the M2. Some of the 
variable amino acids in the homologous M1 and M2 proteins of PR8 are specifically found in the 
Pan99 strain (M1 protein: T167A, R174K, I219V, A227T, A239K; M2 protein: N31S, R54L, Y57H, 
S82SN, G89S). These strain-specific differences may facilitate a more favourable interaction(s) of the 
Pan99-M proteins with the cytoplasmic tails of the two H5N1 surface glycoproteins and/or the RNP 
complex resulting in an increased virus production. However, further mutational analysis will be 
required to test this hypothesis. 
Recently, Rudneva et al. reported that the introduction of the PB1 gene from a low pathogenic avian 
virus of the H5N2 subtype increased the replication of a corresponding 5 + 2 + 1 PR8 reassortant 
compared to the conventional 6 + 2 reassortant [37]. Moreover, two reassorted PR8-based vaccine 
seeds carrying the surface glycoprotein genes of the seasonal Pan99 (H3N2) virus had also received 
the PB1 gene of the epidemic strain [26]. Our finding that the 6 + 2 reassortant #9, expressing only the 
HA and NA genes of Pan99, was a poor producer (Fig. 2) supports the conclusion that a matching 
PB1 gene confers a selective advantage to a corresponding vaccine seed. In case of the engineered 
H5N1 virus, however, we observed that the inclusion of the VN1203-PB1 gene segment in the 5 + 3 
reassortant #7 resulted in a decrease in viral growth. Hence, the contribution of a heterologous PB1 
segment to viral replication and antigen yield may depend on the specific strain backbone and/or the 
species origin of the introduced gene segment and will need to be tested from case to case. 
Most reassortant viruses generated for the present study contained the HA and NA proteins of 
VN1203 instead of the closely related VN1194 used for the generation of NIBRG-14 [17]. These 
closely related surface proteins differ in only one amino acid in the HA (K52T) and three amino acids 
in the NA (F54L, N264D, Y324G). Also, the generated recombinants were built on the Mt Sinai-PR8 
strain instead of the Cambridge-PR8 backbone [38] and, in principle, those differences could also 
contribute to the favourable characteristics of the 5 + 2 + 1 reassortant #4. A low influence of the 
closely related VN1194 and VN1203 glycoprotein genes to vaccine virus growth was recently also 
noted by Horimoto et al. [39]. Interestingly, in this study an even more pronounced effect on growth 
enhancement was observed when the HA and NA glycoproteins were incorporated into the 
background of the PR8-UW (University of Wisconsin) background [39]. The PR8-Mt Sinai strain used 
in our study differs from PR8-Cambridge in a total of 16 amino acids in all internal gene segments, 
whereas there are five amino acid variations compared to PR8-UW (data not shown). Further 
  
systematic side-by-side comparisons in terms of virus propagation and possibly also reassortment of 
the three available PR8 backgrounds may therefore guide a further optimization of vaccine seeds. 
In addition to reassortant #4, we measured an improved yield and HA content also for reassortant #2 
expressing seven segments of PR8 and the HA gene segment of VN1203. A similar observation was 
described in a recent study showing that the NA gene segment of the VN1194 strain contributes to the 
reduced replication and HA quantities of NIBRG-14 [39]. Along the same line, Adamo et al. reported 
an increase in virus yield in reassortants with chimeric NA protein containing the N-terminus of PR8 
and the C-terminus of VN1203 [40]. In our assays we confirmed the recent observation that a PR8 
reassortant with the HA/NA genes of VN1203 mimicking our reassortant #3 replicated as well as the 
parental PR8 [40]. However, this genotype was associated with a strong reduction in virus yield [40] 
and therefore, we did not follow-up on this reassortant in our analysis. Other recombinants generated 
during our study such as reassortants #5 and #6 displayed an increased amount of HA antigen, but 
this was combined with an almost unchanged or decreased replication rate. Thus, the characteristics 
of reassortant viruses are differentially influenced by distinct gene combinations, the consequences of 
which cannot be predicted, but have to be determined empirically. 
Since it has been described that the M proteins influence virion particle shape [33] selected 
reassortant viruses were compared with the parental wild type viruses and NIBRG-14 by transmission 
electron microscopy. It was interesting to note that recombinant PR8 virions had a slightly lower mean 
circumference value than the H5N1 viruses. The results also indicated that NIBRG-14 and the other 
investigated viruses formed mainly spherical virion particles. Thus, the reported low antigen yield of 
NIBRG-14 is not due to a change in virion particle size or morphology. Also, insertions of heterologous 
M gene segments did not influence the particle size to a large extent. We therefore concluded that the 
increased surface glycoprotein content of some viruses was not due to an enlarged particle surface, 
but likely the result from molecular interactions between surface glycoproteins and internal proteins. 
Many influenza vaccine production facilities handle PR8-based seed viruses under conditions of the 
low biosafety level 2. However, alterations in the internal gene composition may possibly alter the low 
pathogenic character of a PR8-based vaccine virus. Therefore, we compared the virulence of the two 
reassortant viruses with the highest improvement scores (#2 and #4) to the parental PR8 and the 
highly pathogenic H5N1 VN1203 strain in the ferret model. Both new reassortant viruses did not 
replicate in the lungs or brains of ferrets and caused only mild clinical symptoms similar as the vaccine 
donor strain PR8. Thus, the attenuating features of a monobasic cleavage site in the H5-HA of 
VN1203 and the low pathogenic strain background of the PR8 virus were maintained in the 
reassortants. These results indicated that the biosafety profile of these viruses is suitable for normal 
vaccine production conditions. We noted for PR8 and reassortant #2 that inspite the presence of virus 
in swab samples from all infected animals on day 3 there was consistently no virus detectable in nasal 
turbinates. This finding may be conferred by the PR8 neuraminidase gene present in both viruses, but 
further work will be required to examine this possibility. 
All together, the data presented here suggest that antigen yield of reassortant H5N1 influenza vaccine 
viruses can be improved by insertion of internal gene segments from strains other than the PR8 
backbone or the virus providing the glycoprotein genes. Further studies should address the question 
whether the M gene segments leading to an improved PR8-based H5N1 vaccine seed virus also 
function in a similar manner in combination with HA and NA gene segments from other virus subtypes. 
The use of reverse genetics to produce pandemic (or seasonal) influenza vaccines with a gene 
constellation other than the classical 6 + 2 format could help to produce sufficient amounts of influenza 
vaccines to protect the population in a short time period against the threat of an influenza pandemic. 
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Tables and Figures 
 
Table 1. Virion dimensions of recombinant viruses. 




 Mean circumference (nm)
b
 
#1 7244 ± 3234 317 ± 69 
#2 8308 ± 2328 354 ± 58 
#4 8774 ± 2298 357 ± 57 
#5 8124 ± 3321 340 ± 74 
#8 7809 ± 1315 346 ± 37 




 Mean area and standard deviation of randomly selected particles of indicated viruses, determined by 
electron microscopy (n = 100 particles per reassortant). 
b
 Mean circumference and standard deviation of randomly selected particles of indicated viruses, 















PR8-HA/NA VN 1203-M Pan R#4 3.2 ± 1.0 2.3 7.4 1 
PR8 R#1 1.8 ± 0.8 2.9 5.2 2 
PR8-HA VN 1203 R#2 1.8 ± 0.8 2.4 4.1 3 
VN 1203-WT-lp R#10 1.7 ± 0.7 1.7 2.9 4 
PR8-HA/NA/M VN 1203 R#6 2.3 ± 0.9 1.2 2.8 5 
PR8-HA/NA VN 1203-M R28 R#5 3.7 ± 1.9 0.6 2.2 6 
PR8-HA/NA/PB1 VN1203 R#7 1.9 ± 0.8 0.4 0.8 7 
NIBRG-14 R#8 1.0 ± 0.0 1.0 1.0 8 
PR8-HA/NA Pan R#9 0.6 ± 0.8 0.6 0.4 9 
PR8-HA/NA VN 1203 R#3 n.d.
d
 2.6 n.d. 
 
VN 1203-WT-hp R#11 n.d.
d





HA/NP ratio x-fold to NIBRG-14 (arbitrarily set to 1) and standard deviation, n = 4. 
b
 Mean EID50/ml x-fold to NIBRG-14 (arbitrarily set to 1), n = 5. 
c
 The total score for each virus is the product of multiplying the relative value for the HA1/NP ratio 
(third column) with the relative value of virus titre (fourth column) in comparison to NIBRG-14. 
d




Figure 1. Gene constellations of generated recombinant/reassortant viruses. The gene constellations 
of newly generated recombinant/reassortant viruses are shown. White squares indicate gene 
segments of the vaccine donor strain A/PR/8/34, light grey squares specify gene segments derived 
from the H5N1-clade 1 strain A/Vietnam/1203/2004 with monobasic cleavage site in the HA gene 
segment. A light grey oval symbolizes HA gene segment of A/Vietnam/1203/2004 with multibasic 
cleavage site, black squares indicate gene segments derived from the H5N1-clade 1 strain 
A/Vietnam/1194/2004. The gene segments of A/chicken/Germany/R28/2003 and 






Figure 2. Growth of reassortant/recombinant viruses in 11-day-old embryonated chicken eggs. 
Embryonated chicken eggs (n = 5 for each virus) were inoculated with 10e3 PFU of the indicated 
viruses. After inoculation, embryonated chicken eggs were incubated at 37 °C for 48 h. In case of 
VN1203-hp/-lp incubation time was decreased to 41 h. Harvested allantoic fluid was used for 
hemagglutination and the EID50/ml values represented by black rhombs were calculated according to 
the method of Reed and Muench [28]. Black bars specify the mean values from all five eggs. 
Significant differences for the recombinant viruses # 1 (PR8), #2 (PR8-HA VN1203) and #3 (PR8-
HA/NA VN1203) compared to NIBRG-14 are indicated by an asterisk (p ≤ 0.05). 
 
  
Figure 3. Analysis of HA1/NP ratio in reassortant viruses. Purified virion preparations of indicated 
recombinant viruses were mock-treated (A) or incubated with PNGaseF (B) prior to separation by SDS 
gel electrophoresis and protein staining with Coomassie Brilliant blue. (C) Single protein bands were 
quantified by densitometry and HA1/NP ratios were calculated and set to 1 for NIBRG-14. Mean 
values of four independent experiments and standard deviations are shown. A significant difference 
(p ≤ 0.05) found for the HA1/NP ratio of a virus compared to NIBRG-14 is indicated by an asterisk. (D) 
Purified virion preparations of the indicated viruses were treated with Tween/ether solution, the surface 
glycoprotein containing phase was collected, denatured, treated with PNGaseF and proteins were 
separated by SDS gel electrophoresis. One representative experiment of at least two independent 





Figure 4. Immuno-negative staining electron microscopy of recombinant and reassortant influenza 
viruses. HA surface glycoprotein was marked with a H5-HA specific antibody and detected by a 
secondary antibody coupled to 5 nm colloidal gold (black dots). (A) recombinant A/PR/8/34 (H1N1), 
(B) A/Vietnam/1203/2004-lp (low pathogenic, H5N1), (C) NIBRG-14 (H5N1), (D) PR8-HA/NA VN1203-







Figure 5. TCID50/ml determination in nasal swabs of infected ferrets. Four groups of ferrets (n = 6) 
were intranasally infected with 0.5 ml containing 10
7
 TCID50 of either A/PR8/34, PR8-HA VN1203 
(R#2), PR8-HA/NA VN1203-M Pan (R#4) or A/Vietnam/1203/2004. On day one to three post infection, 





Figure 6. Virological analysis of organ samples from infected ferrets. Four groups of ferrets were 
intranasally infected with 0.5 ml containing 10
7
 TCID50 of either A/PR/8/34, PR8-HA VN1203 (R#2), 
PR8-HA/NA VN1203-M Pan (R#4) or A/Vietnam/1203/2004. Three animals of each group were 
sacrificed on day 3 and víral loads were titrated by TCID50 determination in organ homogenates of the 
brain (A), lung (B), spleen (C), and nasal turbinates (D). The dotted lines indicate the minimal level of 
detection. 
 
 
